Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on EPS, Stock Up 7.71%

Corvus Pharmaceuticals reported a loss of $0.55 per share, but the stock rose by 7.71% following the earnings release. This positive stock reaction may indicate investor optimism despite the lack of revenue figures and guidance. The absence of detailed commentary from management leaves some uncertainty about future performance.